SCHEMBL714123

SCHEMBL714123

O=C(CO)COC(=O)c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.57
ALDH1A1 P00352 3/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
KDM4E B2RXH2 2/20 0.56
GAA P10253 2/20 0.56
KMT2A Q03164 2/20 0.55
MAPK1 P28482 1/20 0.55
HIF1A Q16665 1/20 0.55
SLC6A2 P23975 1/20 0.55
SLC6A3 Q01959 1/20 0.55
RAB9A P51151 4/20 0.54
NPC1 O15118 2/20 0.54
HPGD P15428 2/20 0.54
LMNA P02545 2/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.51
NFKB1 P19838 1/20 0.51
NFKB2 Q00653 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4586692 0.90 TDP1 (0.63) TDP1ALDH1A1L3MBTL1KDM4EGAA
SCHEMBL712632 0.82 LMNA (0.61) TDP1ALDH1A1L3MBTL1KDM4EGAA
SCHEMBL4523401 0.82 RAB9A (0.57) TDP1ALDH1A1L3MBTL1KDM4EGAA
SCHEMBL3829668 0.82 TDP1 (0.55) TDP1ALDH1A1L3MBTL1KDM4EGAA
SCHEMBL582352 0.81 TDP1 (0.63) TDP1ALDH1A1L3MBTL1KDM4EGAA
SCHEMBL194520 0.81 TDP1 (0.63) TDP1ALDH1A1L3MBTL1KDM4EGAA
SCHEMBL5807503 0.81 LMNA (0.59) ALDH1A1L3MBTL1KDM4EGAASLC6A3
SCHEMBL29175051 0.81 LMNA (0.57) TDP1ALDH1A1KDM4EKMT2AMAPK1
SCHEMBL28216122 0.80 LMNA (0.59) TDP1ALDH1A1L3MBTL1KDM4EGAA
SCHEMBL7421565 0.79 PTPN1 (0.53) TDP1ALDH1A1L3MBTL1KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124780-B2 Benzimidazole compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-02-28 US disclosed
EP-1870409-B1 BENZIMIDAZOLE COMPOUNDS EISAI R&D MAN CO LTD (JP) 2010-05-12 EP disclosed
US-20090203911-A1 BENZIMIDAZOLE COMPOUND MIYAZAWA SHUHEI 2009-08-13 US disclosed
US-7425634-B2 Benzimidazole compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-09-16 US disclosed
EP-1870409-A1 BENZIMIDAZOLE COMPOUND Eisai R&D Management Co., Ltd. (JP) 2007-12-26 EP disclosed
US-20070015782-A1 Benzimidazole compound EISAI CO., LTD. 2007-01-18 US disclosed
US-20070010542-A1 Benzimidazole compound EISAI CO., LTD. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010542-A1 Benzimidazole compound HRH2, GIPR, HRH4 TDP1 4541/4885ALDH1A1 1028/4885L3MBTL1 535/4885
US-20090203911-A1 BENZIMIDAZOLE COMPOUND HRH2, HRH4, HRH1 TDP1 4252/4885ALDH1A1 1053/4885L3MBTL1 299/4885
US-20070015782-A1 Benzimidazole compound HRH2, GIPR, HRH4 TDP1 4541/4885ALDH1A1 1028/4885L3MBTL1 535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.